Assessment of factors related to individuals who were never treated during mass drug administration for lymphatic filariasis in Ambon City, Indonesia.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
03
02
2022
accepted:
17
10
2022
revised:
23
11
2022
pubmed:
12
11
2022
medline:
26
11
2022
entrez:
11
11
2022
Statut:
epublish
Résumé
One challenge to achieving Lymphatic filariasis (LF) elimination is the persistent coverage-compliance gap during annual mass drug administration (MDA) and the risk of ongoing transmission among never treated individuals. Our analysis examined factors associated with individuals who were never treated during MDA. Data were derived from two cross-sectional surveys conducted in Waihaong and Air Salobar Health Center in 2018 and 2019. We analyzed information from 1915 respondents aged 18 years or above. The study outcome was individuals who self-reported never treatment during any round of MDA. All potential predictors were grouped into socio-demographic, health system, therapy and individual factors. Logistic regression analyses were used to examine factors associated with never treatment in any year of MDA. Nearly half (42%) of respondents self-reported they were never treated during any round of MDA. Factors associated with increased odds of never treatment were respondents working in formal sectors (aOR = 1.75, p = 0.040), living in the catchment area of Waihaong Health Center (aOR = 2.33, p = 0.029), and those perceiving the possibility of adverse events after swallowing LF drugs (aOR = 2.86, p<0.001). Respondents reporting difficulty swallowing all the drugs (aOR = 3.12, p<0.001) and having difficulties remembering the time to swallow the drugs (aOR = 1.53, p = 0.049) also had an increased odds of never treatment. The highest odds of never treatment were associated with respondents reporting almost none of their family members took LF drugs (aOR = 3.93, p<0.001). Respondents confident that they knew how to swallow LF drugs had a reduced odds (aOR = 0.26, p<0.001) of never treatment. Efforts to reassure community members about adverse events, specific instructions on how to take LF drugs, and improving awareness that MDA participation is part of one's contribution to promoting community health are essential drivers for uptake with LF drugs during MDA.
Sections du résumé
BACKGROUND
One challenge to achieving Lymphatic filariasis (LF) elimination is the persistent coverage-compliance gap during annual mass drug administration (MDA) and the risk of ongoing transmission among never treated individuals. Our analysis examined factors associated with individuals who were never treated during MDA.
METHODS
Data were derived from two cross-sectional surveys conducted in Waihaong and Air Salobar Health Center in 2018 and 2019. We analyzed information from 1915 respondents aged 18 years or above. The study outcome was individuals who self-reported never treatment during any round of MDA. All potential predictors were grouped into socio-demographic, health system, therapy and individual factors. Logistic regression analyses were used to examine factors associated with never treatment in any year of MDA.
RESULTS
Nearly half (42%) of respondents self-reported they were never treated during any round of MDA. Factors associated with increased odds of never treatment were respondents working in formal sectors (aOR = 1.75, p = 0.040), living in the catchment area of Waihaong Health Center (aOR = 2.33, p = 0.029), and those perceiving the possibility of adverse events after swallowing LF drugs (aOR = 2.86, p<0.001). Respondents reporting difficulty swallowing all the drugs (aOR = 3.12, p<0.001) and having difficulties remembering the time to swallow the drugs (aOR = 1.53, p = 0.049) also had an increased odds of never treatment. The highest odds of never treatment were associated with respondents reporting almost none of their family members took LF drugs (aOR = 3.93, p<0.001). Respondents confident that they knew how to swallow LF drugs had a reduced odds (aOR = 0.26, p<0.001) of never treatment.
CONCLUSIONS
Efforts to reassure community members about adverse events, specific instructions on how to take LF drugs, and improving awareness that MDA participation is part of one's contribution to promoting community health are essential drivers for uptake with LF drugs during MDA.
Identifiants
pubmed: 36367853
doi: 10.1371/journal.pntd.0010900
pii: PNTD-D-22-00158
pmc: PMC9683609
doi:
Substances chimiques
Filaricides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0010900Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Parasit Vectors. 2016 Jan 27;9:29
pubmed: 26813098
Trop Med Infect Dis. 2018 Nov 21;3(4):
pubmed: 30469342
PLoS Negl Trop Dis. 2016 Nov 3;10(11):e0005027
pubmed: 27812107
Trop Med Int Health. 2006 Jun;11(6):862-8
pubmed: 16772008
PLoS Negl Trop Dis. 2010 Jun 29;4(6):e728
pubmed: 20628595
Parasitol Today. 2000 Jul;16(7):298-302
pubmed: 10858649
Ann Trop Med Parasitol. 2005 Apr;99(3):237-42
pubmed: 15829133
Health Policy Plan. 2012 Aug;27(5):384-95
pubmed: 21712348
Epidemics. 2017 Mar;18:56-66
pubmed: 28279457
Lancet Glob Health. 2020 Sep;8(9):e1186-e1194
pubmed: 32827480
BMC Public Health. 2017 May 22;17(1):484
pubmed: 28532397
PLoS Negl Trop Dis. 2016 Jan 14;10(1):e0004358
pubmed: 26766287
Am J Trop Med Hyg. 2007 Dec;77(6):1069-73
pubmed: 18165524
PLoS Negl Trop Dis. 2021 Mar 3;15(3):e0009002
pubmed: 33657090
PLoS Negl Trop Dis. 2010 Mar 23;4(3):e640
pubmed: 20351776
Parasit Vectors. 2018 May 25;11(1):315
pubmed: 29801511
PLoS Med. 2019 Jun 24;16(6):e1002839
pubmed: 31233507
PLoS Negl Trop Dis. 2013 Nov 21;7(11):e2447
pubmed: 24278486
Int J Environ Health Res. 2012;22(5):431-49
pubmed: 22292899
PLoS Negl Trop Dis. 2021 Sep 20;15(9):e0009596
pubmed: 34543269
Trans R Soc Trop Med Hyg. 2014 Sep;108(9):538-49
pubmed: 24728444
BMC Public Health. 2018 Feb 13;18(1):238
pubmed: 29433461
Lancet Glob Health. 2020 Sep;8(9):e1108-e1109
pubmed: 32827473